Passage Bio, Inc. (NASDAQ: PASG) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $7.00 price target on the stock.
Passage Bio, Inc. (PASG)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
PASG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PASG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PASG alerts
High impacting Passage Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PASG
News
- Passage Bio, Inc. (NASDAQ: PASG) had its price target lowered by analysts at Chardan Capital from $7.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business HighlightsGlobeNewswire
- Passage Bio to Participate in Upcoming Investor ConferencesGlobeNewswire
- Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business UpdatesGlobeNewswire
PASG
Earnings
- 3/4/25 - Beat
PASG
Analyst Actions
- 3/4/25 - Chardan Capital
PASG
Sec Filings
- 3/18/25 - Form 4
- 3/18/25 - Form 4
- 3/18/25 - Form 4
- PASG's page on the SEC website